205 related articles for article (PubMed ID: 34434894)
1. A Systematic Review to Clarify the Prognostic Values of CD44 and CD44
Abdoli Shadbad M; Hosseinkhani N; Asadzadeh Z; Derakhshani A; Karim Ahangar N; Hemmat N; Lotfinejad P; Brunetti O; Silvestris N; Baradaran B
Front Oncol; 2021; 11():689839. PubMed ID: 34434894
[TBL] [Abstract][Full Text] [Related]
2. Association of CD44 and CD24 phenotype with lymph node metastasis and survival in triple-negative breast cancer.
Zou W; Yang Y; Zheng R; Wang Z; Zeng H; Chen Z; Yang F; Wang J
Int J Clin Exp Pathol; 2020; 13(5):1008-1016. PubMed ID: 32509072
[TBL] [Abstract][Full Text] [Related]
3. Decreased expression of autophagy protein LC3 and stemness (CD44+/CD24-/low) indicate poor prognosis in triple-negative breast cancer.
Chang SJ; Ou-Yang F; Tu HP; Lin CH; Huang SH; Kostoro J; Hou MF; Chai CY; Kwan AL
Hum Pathol; 2016 Feb; 48():48-55. PubMed ID: 26772398
[TBL] [Abstract][Full Text] [Related]
4. CD44
Wang H; Wang L; Song Y; Wang S; Huang X; Xuan Q; Kang X; Zhang Q
Oncol Lett; 2017 Nov; 14(5):5890-5898. PubMed ID: 29113223
[TBL] [Abstract][Full Text] [Related]
5. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
Riaz N; Idress R; Habib S; Lalani EN
Front Oncol; 2020; 10():1083. PubMed ID: 32850312
[No Abstract] [Full Text] [Related]
6. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).
Ma F; Li H; Wang H; Shi X; Fan Y; Ding X; Lin C; Zhan Q; Qian H; Xu B
Cancer Lett; 2014 Oct; 353(2):153-9. PubMed ID: 25130168
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
8. STAT3 as a promising chemoresistance biomarker associated with the CD44
Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
[TBL] [Abstract][Full Text] [Related]
9. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
10. The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients.
Giatromanolaki A; Sivridis E; Fiska A; Koukourakis MI
Med Oncol; 2011 Sep; 28(3):745-52. PubMed ID: 20405247
[TBL] [Abstract][Full Text] [Related]
11. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.
Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S
Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional profiles of different states of cancer stem cells in triple-negative breast cancer.
Liu M; Liu Y; Deng L; Wang D; He X; Zhou L; Wicha MS; Bai F; Liu S
Mol Cancer; 2018 Feb; 17(1):65. PubMed ID: 29471829
[TBL] [Abstract][Full Text] [Related]
13. Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker.
O'Conor CJ; Chen T; González I; Cao D; Peng Y
Biomark Med; 2018 Jul; 12(7):813-820. PubMed ID: 29902924
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of CD44+/CD24- and Aldehyde Dehydrogenase Enzyme Markers in Cancer Stem Cells as Prognostic Indicators for Triple-Negative Breast Cancer.
Escudero Mendez L; Srinivasan M; Hamouda RK; Ambedkar B; Arzoun H; Sahib I; Fondeur J; Mohammed L
Cureus; 2022 Aug; 14(8):e28056. PubMed ID: 36120232
[TBL] [Abstract][Full Text] [Related]
15. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
[TBL] [Abstract][Full Text] [Related]
16. Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN.
Wu Y; Sarkissyan M; Elshimali Y; Vadgama JV
PLoS One; 2013; 8(10):e78259. PubMed ID: 24167614
[TBL] [Abstract][Full Text] [Related]
17. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast.
Gudadze M; Kankava Q; Mariamidze A; Burkadze G
Georgian Med News; 2014 Mar; (228):81-7. PubMed ID: 24743129
[TBL] [Abstract][Full Text] [Related]
18. Metalloprotease-dependent activation of EGFR modulates CD44
Wise R; Zolkiewska A
Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
[TBL] [Abstract][Full Text] [Related]
19. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas.
Mylona E; Giannopoulou I; Fasomytakis E; Nomikos A; Magkou C; Bakarakos P; Nakopoulou L
Hum Pathol; 2008 Jul; 39(7):1096-102. PubMed ID: 18495204
[TBL] [Abstract][Full Text] [Related]
20. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
